Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health ...

From consumer products to clinical trials, anything that is designed without input from its intended recipients will likely feel disconnected from their needs. Conversely, systemically gathering their ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...